Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Neuroblastoma 2Wilms Tumor 1Sarcoma, Ewing 1Retinoblastoma 1Glioma 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
racotumomab × CNS × Clear all
NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed
39 enrolled
CNS

Neuroblastoma

NCT01598454 2015-07-29

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Laboratorio Elea Phoenix S.A.

Phase 1 Completed
15 enrolled
CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡